U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Advanced Renal Cell Carcinoma

AI-generated NewsSnap summary based on source reporting.
Published: 2026-09-28
Category: health
Source: News Release

The U.S. Food and Drug Administration (FDA) has approved the combination of WELIREG® (belzutifan) and LENVIMA® (lenvatinib) for certain adult patients with previously treated advanced renal cell carcinoma with a clear cell component (ccRCC). This approval is based on results from the Phase 3 LITESPARK-011 trial.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai